| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/20000 | Human,Mouse,Rat |
| Aliases | THPO; MGDF; Thrombopoietin; C-mpl ligand; ML; Megakaryocyte colony-stimulating factor; Megakaryocyte growth and development factor; MGDF; Myeloproliferative leukemia virus oncogene ligand |
| Entrez GeneID | 7066; |
| WB Predicted band size | 38kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthesized peptide derived from the Internal region of human TPO. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.5%BSA and 50% glycerol. |
+ +
以下是关于TPO抗体的3-4篇参考文献的简要概括(文献名称、作者及摘要内容)：
1. **《Thyroid Autoimmunity》**
- **作者**: Rapoport, B.; McLachlan, S.M.
- **摘要**: 该综述探讨了甲状腺自身免疫中TPO抗体的作用，强调其在桥本甲状腺炎和Graves病中的诊断价值，并分析了抗体与甲状腺细胞破坏机制的关系。
2. **《Hashimoto Thyroiditis: Clinical and Diagnostic Criteria》**
- **作者**: Caturegli, P.; De Remigis, A.; Chuang, K.
- **摘要**: 研究总结了桥本甲状腺炎的临床特征，指出TPO抗体作为关键血清标志物，其阳性率与甲状腺功能减退进展显著相关，可用于早期筛查。
3. **《The Role of Thyroid Peroxidase Antibodies in Predicting Thyroid Dysfunction》**
- **作者**: Zaletel, K.; Gaberscek, S.
- **摘要**: 通过队列研究分析，表明TPO抗体阳性患者未来发展为甲状腺功能异常的风险显著增高，尤其在妊娠期女性中具有重要筛查意义。
4. **《TPO Antibodies: An Update on Their Role in Pathogenesis》**
- **作者**: McLachlan, S.M.; Rapoport, B.
- **摘要**: 该文献更新了TPO抗体的生物学特性，包括其表位识别、与甲状腺细胞凋亡的关联，以及作为治疗靶点的潜在研究方向。
---
以上文献均为示例，实际引用时需核对具体来源及内容准确性。如需正式参考文献格式，建议通过PubMed或学术数据库查询具体文献的DOI及期刊信息。
**Background of TPO Antibodies**
Thyroid peroxidase (TPO) antibodies are autoantibodies targeting thyroid peroxidase, an enzyme critical for thyroid hormone synthesis. TPO catalyzes iodide oxidation and thyroglobulin iodination, essential steps in producing thyroxine (T4) and triiodothyronine (T3). In autoimmune thyroid disorders, the immune system mistakenly identifies TPO as foreign, triggering antibody production.
TPO antibodies are hallmark biomarkers of autoimmune thyroid diseases (AITDs), including Hashimoto’s thyroiditis (chronic lymphocytic thyroiditis) and Graves’ disease. Elevated TPO antibodies are detected in ~90% of Hashimoto’s cases, correlating with thyroid inflammation and eventual hypothyroidism. In Graves’ disease, their presence often coexists with TSH receptor antibodies, indicating broader autoimmune activity. These antibodies also aid in diagnosing postpartum thyroiditis, silent thyroiditis, and predicting thyroid dysfunction risk in euthyroid individuals.
Clinically, TPO antibody testing helps differentiate autoimmune causes from other thyroid disorders. Their levels may correlate with disease severity but do not consistently predict progression. Around 10-15% of healthy individuals may have low TPO antibody titers, often linked to genetic predisposition or subclinical autoimmunity.
Research highlights their role in understanding AITD pathogenesis, particularly T-cell-mediated thyroid destruction. Additionally, TPO antibodies are associated with non-thyroid autoimmune conditions (e.g., type 1 diabetes, rheumatoid arthritis), underscoring systemic immune dysregulation. Despite diagnostic utility, their exact pathogenic mechanisms remain partially unclear, warranting further investigation.
×
